Format

Send to

Choose Destination
Annu Rev Genomics Hum Genet. 2014;15:371-94. doi: 10.1146/annurev-genom-091212-153527. Epub 2014 Apr 18.

Therapeutics based on stop codon readthrough.

Author information

1
Department of Microbiology and Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294; email: kkeeling@uab.edu , xjxue@uab.edu , gwengunn@uab.edu , dbedwell@uab.edu.

Abstract

Nonsense suppression therapy encompasses approaches aimed at suppressing translation termination at in-frame premature termination codons (PTCs, also known as nonsense mutations) to restore deficient protein function. In this review, we examine the current status of PTC suppression as a therapy for genetic diseases caused by nonsense mutations. We discuss what is currently known about the mechanism of PTC suppression as well as therapeutic approaches under development to suppress PTCs. The approaches considered include readthrough drugs, suppressor tRNAs, PTC pseudouridylation, and inhibition of nonsense-mediated mRNA decay. We also discuss the barriers that currently limit the clinical application of nonsense suppression therapy and suggest how some of these difficulties may be overcome. Finally, we consider how PTC suppression may play a role in the clinical treatment of genetic diseases caused by nonsense mutations.

KEYWORDS:

nonsense mutation; nonsense suppression therapy; premature termination codons; readthrough

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center